申请人:Hoffmann-La Roche Inc.
公开号:US07528136B2
公开(公告)日:2009-05-05
The present invention relates to a compound of formula I
wherein
R1,
R2,
R3, R4, R5,
X, n, and o are as defined herein and to a pharmaceutically acceptable acid addition salt thereof which are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
本发明涉及一种式子为I的化合物,其中R1、R2、R3、R4、R5、X、n和o的定义如本文所述,并且涉及其药学上可接受的酸盐,它们是高潜力的NK-3受体拮抗剂,用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍(ADHD)。